secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001140361-25-010595
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys reports 52% revenue growth in 2024; net loss widens to $18.8M; cash runway into Q3 2025
--------------------------------------------------------------------------------

- Revenue $1.63M, up 52% YoY; net loss $18.8M ($0.85/sh) vs $14.2M ($0.93/sh) in 2023.
- Cash $3.5M at year-end; subsequent $5.4M raise; expects runway into Q3 2025.
- R&D $8.2M (+14%) and sales/marketing $4.0M (6x increase) due to FemBloc/FemaSeed launch.
- FemBloc received European approval; partnerships with CNY Fertility, HRC Fertility, Boston IVF for FemaSeed.
- CEO guides U.S. revenue to increase ~50% in Q1 2025 vs Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125010595/0001140361-25-010595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125010595/ef20046254_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-010595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer